Avidity Biosciences completes enrolment in Phase 3...
News
July 29, 2025
Avidity Biosciences completes enrolment in Phase 3 del-desiran trial in DM1
29 July 2025 - Avidity Biosciences Inc (Nasdaq:RNA), a biopharmaceutical company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), announced on M...
29 July 2025 - Avidity Biosciences Inc (Nasdaq:RNA), a biopharmaceutical company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), announced on M...
Premium Content
This article is available to subscribers only. Subscribe to read the full article.
Category:
Technology